To include your compound in the COVID-19 Resource Center, submit it here.

Generx: Phase I/II

CLTX and partner Berlex Laboratories reported that in a U.S. 79-patient, double-blind, placebo-controlled trial of 5 ascending doses, Generx

Read the full 193 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE